Learn about ovarian cancer treatment and research at virtual patient education event

May 26, 2022 Providence Cancer Institute of Oregon

Join Providence Cancer Institute of Oregon and Ovarian Cancer Alliance of Oregon and SW Washington for a free, virtual patient education event for ovarian cancer patients and their caregivers.

Christopher Darus, M.D., MS, gynecologic oncologist and medical director of Providence Gynecologic Oncology Program, will give an update on the latest developments in ovarian cancer diagnoses, treatments, research and clinical trials.

Virtual event details

June 29, 2022
7:00 p.m. to 8:15 p.m.

Register here

About Dr. Christopher Darus

Dr. Christopher Darus joined Providence Cancer Institute in October 2020 as medical director of Providence Gynecologic Oncology Program. He previously was director of gynecologic cancer research at Maine Medical Center in Portland, Maine.

Dr. Darus graduated from Wright State University School of Medicine in 2000 and completed his residency in Obstetrics and Gynecology at University of Colorado Health Sciences Center in 2004. Following his residency, he completed a fellowship in Gynecologic Oncology at the University of Virginia Health System in 2007. This rigorous training prepared Dr. Darus to offer advanced surgical and medical treatment techniques to his patients.

Dr. Darus has an acute understanding of the impact of a gynecologic cancer diagnosis and treatment on his patients and their families. He emphasizes the importance of treating the whole patient while utilizing the skills and strengths of the multidisciplinary team of providers at Providence Cancer Institute. His clinical interests include minimally invasive surgery, clinical trials and cancer genomics.

Dr. Darus is an avid cook and enjoys scuba diving and underwater photography. He lives in Portland with his wife and children.

Exceptional gynecologic cancer care

The Providence Gynecologic Oncology Program provides specialized care for women with suspected or known gynecologic malignancies and complex precancerous conditions. We offer care at two locations: Robert W. Franz Cancer Center at Providence Portland Medical Center and Providence St. Vincent Medical Center.

Through the program, patients have access to advanced treatments, such as robotic surgery, immunotherapy, and the latest research and clinical trials. Patients also have the convenience of receiving all their care in a single location. Learn more.

Related resources

Clinical trials: Leading breakthroughs in cancer research

Clinical trial aims to help premenopausal women at risk for ovarian cancer

Gynecologic oncology care now available at Providence Cancer Institute

Welcome to your journey for creating a healthier you

Learn about ovarian cancer treatment and research at virtual patient education event

Previous Article

Next Article

Learn about ovarian cancer treatment and research at virtual patient education event

Previous Article

Next Article

Other content in this Stream

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.